Drug Profile
BAY 1143269
Alternative Names: BAY-1143269Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom (PO)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in USA (PO)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in United Kingdom (PO)